Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Equivalents (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Cash & Equivalents readings, the most recent being $713.0 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 206.01% to $713.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $713.0 million, a 206.01% increase, with the full-year FY2025 number at $713.0 million, up 206.01% from a year prior.
  • Cash & Equivalents hit $713.0 million in Q4 2025 for Neurocrine Biosciences, up from $340.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $713.0 million in Q4 2025 to a low of $103.8 million in Q1 2023.
  • Median Cash & Equivalents over the past 5 years was $270.4 million (2022), compared with a mean of $286.9 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 61.58% in 2023 and later soared 281.79% in 2024.
  • Neurocrine Biosciences' Cash & Equivalents stood at $344.0 million in 2021, then dropped by 21.31% to $270.7 million in 2022, then decreased by 4.29% to $259.1 million in 2023, then dropped by 10.07% to $233.0 million in 2024, then surged by 206.01% to $713.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $713.0 million (Q4 2025), $340.2 million (Q3 2025), and $264.0 million (Q2 2025) per Business Quant data.